<DOC>
	<DOCNO>NCT01576146</DOCNO>
	<brief_summary>The purpose study evaluate long term safety efficacy thrice weekly intravenous ( IV ) administration KAI-4169 treatment secondary hyperparathyroidism ( SHPT ) hemodialysis subject .</brief_summary>
	<brief_title>Open-label Study Assess Long-term Safety Efficacy AMG 416 ( Also Known KAI-4169 ) Patients With Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Subject provide write informed consent . Subject participate parent study , KAI4169005 Subject pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Clinical Trial , Phase 2</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Secondary Hyperparathyroidism</keyword>
	<keyword>Chronic kidney disease-mineral bone disorder</keyword>
	<keyword>Parathyroid hormone</keyword>
</DOC>